Clinically, miR-497 expression was downregulated in breast cancer specimens compared to normal breast tissues, which is negatively associated with pathological stage, lymphatic metastasis, larger tumor size, and positive HER-2; also, its upregulation is correlated with better prognosis in breast cancer patients (10). This evidence concerns the gene ERBB2 and breast carcinoma.